Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 9/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454901 | 0.87 | CYP2D6 (0.42) | CYP2D6CHRM2CHRM3TSHRCYP3A4 | |
| SCHEMBL4522977 | 0.87 | CYP2D6 (0.47) | CYP2D6CHRM2CHRM3TSHRCYP3A4 | |
| SCHEMBL4519652 | 0.85 | CYP2D6 (0.41) | CYP2D6CHRM2CHRM3TSHRCYP3A4 | |
| SCHEMBL4452402 | 0.79 | CYP2D6 (0.33) | CYP2D6CHRM2CHRM3TSHRCYP3A4 | |
| SCHEMBL6079416 | 0.78 | CYP2D6 (0.45) | CYP2D6CHRM2CHRM3TSHRCYP3A4 | |
| SCHEMBL4454104 | 0.77 | POLB (0.44) | ALDH1A1MAPK1SIGMAR1 | |
| SCHEMBL4449570 | 0.76 | POLB (0.43) | ALDH1A1L3MBTL1 | |
| SCHEMBL4534459 | 0.76 | SIGMAR1 (0.44) | CYP2D6CHRM2CHRM3TSHRCYP3A4 | |
| SCHEMBL4527417 | 0.75 | CYP2D6 (0.46) | CYP2D6CHRM2CHRM3TSHRCYP3A4 | |
| SCHEMBL4564514 | 0.74 | F10 (0.60) | CYP2D6TSHRCYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170844-A1 | Spiro Tetracyclic Compound | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-2020411-A1 | SPIRO TETRACYCLIC COMPOUND | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170844-A1 | Spiro Tetracyclic Compound | KCNH1, TFPI, KCNN2 | CYP2D6 369/4885CHRM2 3831/4885CHRM3 3619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.